Selective serotonin reuptake inhibitors and the risk of congenital anomalies anomalies: a systematic review of current meta-analyses

Basit Öğe Kaydı
dc.contributor.authorUguz, Faruk
dc.date.accessioned2024-02-23T14:20:36Z
dc.date.available2024-02-23T14:20:36Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjective:A review of current meta-analyses examining the relationship between maternal use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and congenital anomalies. Methods:PubMed was searched for meta-analyses published in English language between January 2010 and April 2020 by using the following combinations of key words:meta-analysis, pregnancy, antidepressant, SSRI, citalopram, escitalopram, fuloxetine, paroxetine, sertraline, fluvoxamine, neonatal outcome, birth outcome, congenital malformation, congenital anomaly, birth defect, cardiac malformation and heart defect. Results:A total of 15 meta-analyses met the search criteria. These meta-analyses consistently suggested a significant positive association between the use of SSRIs in general and paroxetine and fluoxetine in particular and the risk of major congenital anomalies. The data also showed a consistency in increased cardiovascular defects in infants due to maternal use of paroxetine. The risk of cardiovascular defects in infants of women using SSRIs in general and fluoxetine and sertraline in particular was controversial. Conclusion:Further large-scale prospective observational studies and meta-analyses on the effects of individual SSRIs other than paroxetine, especially escitalopram and fluvoxamine, are required to reach definitive conclusions.en_US
dc.identifier.doi10.1080/14740338.2020.1832080
dc.identifier.endpage1604en_US
dc.identifier.issn1474-0338
dc.identifier.issn1744-764X
dc.identifier.issue12en_US
dc.identifier.pmid33001713en_US
dc.identifier.scopus2-s2.0-85092404539en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1595en_US
dc.identifier.urihttps://doi.org/10.1080/14740338.2020.1832080
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13229
dc.identifier.volume19en_US
dc.identifier.wosWOS:000579084500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Opinion On Drug Safetyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPregnancyen_US
dc.subjectCongenital Malformationsen_US
dc.subjectCardiac Malformationsen_US
dc.subjectAntidepressanten_US
dc.subjectSsrien_US
dc.titleSelective serotonin reuptake inhibitors and the risk of congenital anomalies anomalies: a systematic review of current meta-analysesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu